ArticleFrontiers in psychiatry2026
Mental health problems and social functioning across different treatment stages in Chinese subjects with gender dysphoria in Hong Kong.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study assesses the prevalence of psychiatric comorbidities, functioning, and adjustment difficulties of patients undergoing different gender-affirming treatment stages at the centralized Gender Identity Disorder (GID) clinic in Hong Kong. Method: This cross-sectional study consecutively recruited patients with gender dysphoria according to the DSM-5 criteria in the GID clinic from Oct 2017 to Aug 2018. They were assessed with the Structured Clinical Interview for DSM Axis I disorders (SCID-I) and the Structured Clinical Interview for DSM Axis II personality disorders (SCID-II). Depressive and anxiety symptoms, self-esteem, quality of life and social functioning were measured. Results: Eighty-nine subjects were recruited. The current and lifetime prevalence of DSM-IV Axis I disorders were 12.4% and 46.1% respectively. Prevalence of personality disorder was 36%. Among the current and lifetime Axis I disorders, depressive disorders were the most common (10.1%, 39.3%). Avoidant personality disorder was the most common Axis II disorder (16.9%). In regression analyses, subjects who received gender-affirming surgery and gender-affirming hormone therapy were associated with better overall (p = 0.034) and psychological domain (p < 0.001) of quality of life and self-esteem (p = 0.033). Gender-affirming hormone therapy alone was associated with better psychological domain (p = 0.001) of quality of life and lower levels of depressive symptoms (p = 0.049). Higher perceived social support was associated with lower levels of depressive symptoms (p < 0.001), better overall (p < 0.001) and psychological domain (p<0.001) of quality of life, and self-esteem (p < 0.001). Conclusions: Lifetime comorbidity is common in Hong Kong GID Clinic patients with gender dysphoria. Gender-affirming treatments and social support are linked to a better quality of life and self-esteem. Hormone therapy and social support are associated with lower levels of depressive symptoms. Our finding preliminarily suggested better mental health and adjustment in patients with favorable social support who received gender-affirming treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.